Authors:

Xingbei Dong (Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology) Jiuliang Zhao (Peking Union Medical College Hospital, Chinese Academy of Medical Sciences) Junyan Qian (Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology) Wei Wei (Tianjin Medical University General Hospital) Miaojia Zhang (The First Affiliated Hospital of Nanjing Medical University(Jiangsu Province Hospital)) Xiao Zhang (Department of Rheumatology, Guangdong General Hospital, Guangzhou, China) Xiaofei Shi (the First Affiliated Hospital of Henan University of science and Technology, Luoyang, China) Yisha Li (Xiangya Hospital, Central South University, Changsha, China) Xiaoping Hong (Shenzhen People's Hospital, Shenzhen, China) Qiang Shu (Qilu Hospital of Shandong University, Jinan, China) Shuhong Chi (General Hospital of Ningxia Medical University, Yinchuan, China) Xin Dong (Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China) Ping Zhu (Department of Clinical Immunology, Xijing Hospital, and National Translational Science Center for Molecular Medicine, Fourth Military Medical University) Rong Zhang (the First Hospital of China Medical University, Shenyang, China) Zhuoli Zhang (Peking University First Hospital) Hongfeng Zhang (The First Hospital of Dalian Medical University) Xinwang Duan (The Second Affiliated Hospital of Nanchang University) Jing Xue (the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China) Shuhong Zhou (Gansu Provincial Hospital, Lanzhou, China) Hongbin Li (Affiliated Hospital of Inner Mongolia Medical College) Dan Chen (the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China) Junwei Zhang (Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China) Yanhong WANG (Peking Union Medical College) Zhuang Tian (Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital) Yong-Tai Liu (Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital) Mengtao Li (Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology) Xiaofeng ZENG (Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology) Qian Wang (Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education)

1	Improvements and challenges of long-term survival in patients with
2	systemic lupus erythematosus-associated pulmonary arterial
3	hypertension: A 10-year multi-center cohort study
4	
5	Short title: Improved survival and challenges of SLE-PAH
6	
7	Xingbei Dong, MD.1,2,3,4,*, Jiuliang Zhao, MD.1,2,3,4,*, Junyan Qian, MD.1,2,3,4,*, Wei
8	Wei, MD.5,*, Miaojia Zhang, MD.6, Xiao Zhang, MD.7, Xiaofei Shi, MD.8, Yisha Li,
9	MD.9, Xiaoping Hong, MD.10, Qiang Shu, MD.11, Shuhong Chi, MD.12, Xin Dong,
10	MD.13, Ping Zhu, MD.14, Rong Zhang, MD.15, Zhuoli Zhang, MD.16, Hongfeng Zhang,
11	MD.17, Xinwang Duan, MD.18, Jing Xue, MD.19, Shuhong Zhou, MD.20, Hongbin Li,
12	MD.21, Dan Chen, MD.22, Junwei Zhang, BD.23, Yanhong Wang, Ph.D.24, Zhuang Tian,
13	MD.25, Yongtai Liu, MD.25, Mengtao Li, MD.1,2,3,4,‡, Xiaofeng Zeng, MD.1,2,3,4,‡,
14	Qian Wang, MD.1,2,3,4,‡
15	
16	*Xingbei Dong, Jiuliang Zhao, Junyan Qian, and Wei Wei contributed equally to this study.
17	‡Correspondence to: Prof Mengtao Li, +86-13911788572, mengtao.li@cstar.org.cn; Prof

+86-13681211155, <u>wangqian_pumch@126.com</u>. Department of Rheumatology and

Xiaofeng Zeng, +86-13501069845, <u>xiaofeng.zeng@cstar.org.cn</u>; Prof Qian Wang,

- Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of

21	Medical Sciences, Peking Union Medical College. National Clinical Research Center for
22	Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &
23	Technology. State Key Laboratory of Complex Severe and Rare Diseases, Peking Union
24	Medical College Hospital. Key Laboratory of Rheumatology and Clinical Immunology,
25	Ministry of Education, Beijing 100730, China.
26	
27	1. Department of Rheumatology and Clinical Immunology, Peking Union Medical
28	College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical
29	College.
30	2. National Clinical Research Center for Dermatologic and Immunologic Diseases
31	(NCRC-DID), Ministry of Science & Technology.
32	3. State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical
33	College Hospital.
34	4. Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education,
35	Beijing 100730, China.
36	5. Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin,
37	China.
38	6. Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical
39	University, Nanjing, China.
40	7. Department of Rheumatology, Guangdong General Hospital, Guangzhou, China.
41	8. Department of Rheumatology, the First Affiliated Hospital of Henan University of
42	science and Technology, Luoyang, China.

43	9. Department of Rheumatology, Xiangya Hospital, Central South University, Changsha,
44	China.
45	10. Department of Rheumatology, Shenzhen People's Hospital, Shenzhen, China.
46	11. Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, China.
47	12. Department of Rheumatology, General Hospital of Ningxia Medical University,
48	Yinchuan, China.
49	13. Department of Rheumatology, Beijing Chao-Yang Hospital, Capital Medical University,
50	Beijing, China.
51	14. Department of Clinical Immunology, PLA Specialised Research Institute of
52	Rheumatology and Immunology, Xijing Hospital, Fourth Military Medical University,
53	Xi'an, China.
54	15. Department of Rheumatology, the First Hospital of China Medical University,
55	Shenyang, China.
56	16. Department of Rheumatology and Clinical Immunology, Peking University First
57	Hospital, Beijing, China.
58	17. Department of Rheumatology, the First Affiliated Hospital of Dalian Medical
59	University, Dalian, China.
60	18. Department of Rheumatology, the Second Affiliated Hospital of Nanchang University,
61	Nanchang, China.
62	19. Department of Rheumatology, the Second Affiliated Hospital of Zhejiang University
63	School of Medicine, Hangzhou, China.
64	20. Department of Rheumatology, Gansu Provincial Hospital, Lanzhou, China.

65	21. Department of Rheumatology, the Affiliated Hospital of Inner Mongolia Medical
66	University, Hohhot, China.
67	22. Department of Rheumatology, the First Affiliated Hospital of Wenzhou Medical
68	University, Wenzhou, China.
69	23. Department of Critical Respiratory Medicine, Beijing Chao-Yang Hospital, Capital
70	Medical University, Beijing, China.
71	24. Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences,
72	Chiness Academy of Medical Sciences and Peking Union Medical College, Beijing,
73	China.
74	25. Department of Cardiology, Peking Union Medical College Hospital, Peking Union
75	Medical College and Chinese Academy of Medical Sciences, Beijing, China.

77 Word Count : 5014

- 78 What is new?
- This is the largest multi-center prospective cohort study of SLE-PAH with the longest
 follow-up period describing changes in the characteristics, treatment regimen, and
 long-term survival of patients with SLE-PAH.
- Our study showed that the 5-year survival rate of patients with SLE-PAH has
 increased remarkably from 77.5% to 88.1% during the last decade.
- Our study demonstrated that reaching lupus low-disease-activity state is independently
 associated with reduced mortality. Significantly more patients reached low-risk profile
- 86 of PAH during follow-up with initiation of intensive immunosuppressive therapy.

88 What are the clinical implications?

• Our study emphasised on the importance of achieving dual treatment goals for both

- 90 SLE and PAH (dual treat-to-target strategy).
- Earlier detection of PAH in patients with SLE, timely initiation of intensive
- 92 immunosuppressive therapy, and upfront combination PAH-targeted therapy benefit
- 93 patients in achieving PAH low-risk profile.

94 Abstract

95 Background: Prior studies indicated improved survival in systemic sclerosis-associated
96 pulmonary arterial hypertension (PAH) patients, but trends in systemic lupus
97 erythematosus-associated PAH (SLE-PAH) survival remained unclear.

Methods: Analysing SLE-PAH patients from the nationwide CSTAR-PAH cohort, we
divided them into two cohorts: A (2011-2016) and B (2016-2021), based on baseline right
heart catheterization dates. We compared clinical characteristics, mortality, and treatment
outcomes between these cohorts and with idiopathic PAH (IPAH) patients.

102 **Results:** We enrolled 610 and 104 patients with SLE-PAH and IPAH, respectively. Patients 103 with SLE-PAH were younger, had a higher proportion of low-risk patients, and had a significantly higher 10-year survival rate than those with IPAH (66.6% vs. 44.1%, p < 104 105 0.001). Cohort B had a longer 6-min walk distance, lower mean pulmonary arterial pressure and pulmonary vascular resistance, a better-preserved cardiac index, and less right 106 ventricular dilation than cohort A. More patients in cohort B received intensive 107 immunosuppressant- and PAH-targeted therapies. The 5-year survival rate was 108 109 significantly higher in cohort B (88.1% vs. 77.5%, p = 0.006). Reaching low-risk profile of PAH (hazard ratio [HR] 0.34, 95% confidence interval [CI] 0.15-0.79, p = 0.012) and 110 111 reaching lupus low-disease-activity state (HR 0.33, 95% CI 0.14-0.82, p = 0.016) were 112 independent predictors of survival. The rate of achieving low-risk profile for PAH was considerably higher in patients initially treated with intensive immunosuppressive and 113 dual-PAH-targeted therapies. 114

115 Conclusions: Over the last decade in China, the clinical characteristics of patients with 116 SLE-PAH have evolved and survival has improved. Early PAH detection and dual 117 treatment-to-target strategies for both PAH and SLE have contributed to this improvement 118 in survival.

119

120 Keywords: pulmonary arterial hypertension, systemic lupus erythematosus, long-term
121 survival, lupus low-disease-activity state, dual treat-to-target strategy

122 Introduction

Pulmonary arterial hypertension (PAH) is a pathophysiological disorder characterised by
progressive pressure elevation in the pulmonary circulation due to pulmonary vascular
disease, eventually leading to right heart failure¹. Connective tissue disease (CTD) is one
of the major aetiologies of PAH, accounting for 13.1%–25.3% of cases of PAH^{2.4}.
Meanwhile, PAH is a severe and frequent complication of CTD and remains a leading
cause of mortality in patients with CTD⁵.

Over the last two decades, the development of PAH medications targeting the endothelin-1, nitric oxide, and prostaglandin I₂ pathways and the constant refinement of treatment strategies have led to improvements in the clinical outcomes of patients with PAH^{3, 4, 6}. A recent study performed at Johns Hopkins Pulmonary Hypertension Center reported that transplant-free survival markedly improved in patients with systemic sclerosis (SSc)-associated PAH (SSc-PAH)⁷.

Unlike in Western populations, systemic lupus erythematosus (SLE)-associated PAH (SLE-PAH) is the leading cause of CTD-associated PAH (CTD-PAH) in China, accounting for approximately 50% of the cases⁸. SLE-PAH shows very different outcomes from SSc-PAH and other types of pulmonary hypertension⁹⁻¹¹, probably because of the remarkable inflammatory nature of SLE-PAH. However, whether the evolving diagnostic and treatment strategies benefit patients with SLE-PAH in a real-world setting remains unclear.

142 Therefore, we conducted this multi-center prospective cohort study to explore changes in

the clinical characteristics, initial treatment strategy, treatment goal achievement, and
long-term survival of patients with SLE-PAH over the past decade. We also discuss
possible reasons for the improvement in survival and describe the challenges that remain in
the disease management of SLE-PAH.

147

148 Methods

149 Study design

The Chinese SLE Treatment and Research Group (CSTAR) PAH cohort is a nationwide 150 multi-center prospective cohort established in 2006, involving 21 qualified CTD-associated 151 PAH referral centers (Supplement Table 1) in China^{12, 13}. Ethical approval was granted by 152 by the Institutional Review Board of Peking Union Medical College Hospital (PUMCH) 153 (JS-2038). All patients in the cohort met the 1997 American College of Rheumatology 154 classification¹⁴ or the 2012 Systemic Lupus International Collaborating Clinics 155 classification¹⁵ for SLE. PAH was defined as a resting mean pulmonary arterial pressure 156 (mPAP) of \geq 25 mmHg, pulmonary arterial wedge pressure of \leq 15 mmHg, and pulmonary 157 vascular resistance (PVR) of >3 Wood units (WU) obtained by right heart catheterisation 158 159 (RHC). Patients with SLE-PAH diagnosed between 1 June 2011, and 31 May 2021, were 160 enrolled in the study. Patients with idiopathic PAH (IPAH) were consecutively recruited from Beijing Chaoyang Hospital as the control group during the same period to 161 simultaneously describe the baseline characteristics and survival of patients with SLE-PAH. 162 Patients who did not fulfil the hemodynamic definition of pre-capillary pulmonary 163

164 hypertension and those associated with conditions such as human immunodeficiency virus infection, portal hypertension, congenital heart disease, heart failure with reduced ejection 165 fraction, severe lung disease, or pulmonary embolism were excluded. Severe lung disease 166 167 was defined as a total lung capacity <70% of the predicted value or signs of extensive pulmonary fibrosis on high-resolution chest computed tomography¹⁶. Eligible patients with 168 SLE-PAH were divided into cohorts A and B according to the date of RHC diagnosis. 169 170 Cohort A was recruited from 1 June 2011, to 31 May 2016, and cohort B underwent RHC from 1 June 2016, to 31 May 2021. 171

172 Data collection

173 Baseline was defined as the time of RHC diagnosis. The following baseline variables were selected: age; sex; disease duration from diagnosis of SLE; onset symptoms of PAH; 174 175 laboratory results, including serum chemistry panel and N-terminal pro-brain natriuretic 176 peptide (NT-proBNP) level; World Health Organization function class (WHO-FC); 6-minute walk distance (6-MWD); hemodynamic 177 parameters; transthoracic echocardiogram (TTE) findings; pulmonary function test (PFT); SLE Disease Activity 178 Index 2000 (SLEDAI-2K)¹⁷; and initial treatment regimens. Patients were also stratified 179 according to their baseline characteristics using variables selected from the risk assessment 180 strategy proposed in the 2022 ECS/ERS Guidelines¹⁸ (the parameters are shown in 181 182 Supplement Table 2). The low-, intermediate-, and high-risk groups were assigned scores of 1, 2, and 3, respectively. The average score was then calculated for each patient and 183 184 rounded to the nearest integer. The primary endpoint was the all-cause mortality rate. The secondary endpoint was reaching low-risk profile of PAH according to the four-stratum 185

risk assessment model COMPERA 2.0¹⁹. Moreover, follow-up data were collected at each clinic visit to determine the achievement of lupus low-disease-activity state (LLDAS)²⁰, which was determined if (1) SLE-DAI-2K \leq 4, with no activity in major organ systems; (2) no new lupus disease activity compared with the last assessment; (3) physician global assessment score \leq 1; and (4) prednisolone (or equivalent) dose \leq 7.5 mg daily with well-tolerated maintenance doses of immunosuppressants.

192 Statistical analysis

193 Mean and standard deviation were used to describe the parametric data. The independent t-test, analysis of variance (ANOVA), and Kruskal-Wallis H test were used to compare 194 195 continuous variables. The chi-squared test or Fisher's exact test was used to compare categorical variables. Statistical significance was set at p <0.05. Survival analysis was 196 197 performed using the Kaplan-Meier method, and the log-rank test was used to compare 198 survival rates. Univariate and multivariate Cox regression analyses were used to identify factors associated with all-cause mortality. Because reaching low-risk profile of PAH and 199 reaching LLDAS of SLE were time-dependent covariates, we applied time-dependent Cox 200 201 regression to avoid immortal time bias. Also, additional survival analyses using propensity score matching for age, sex, and cardiac index (CI) were performed, and the proportion of 202 patients reaching a low-risk profile of PAH during follow-up was compared between 203 204 matched samples with different treatment regimens. SPSS version 26 (SPSS, Chicago, IL, 205 USA) was used for all statistical analyses.

207 **Results**

208 Baseline clinical characteristics of patients with SLE-PAH and IPAH

209 In total, 610 eligible patients with SLE-PAH were included in this study. Among these, 314

and 296 patients were included in cohorts A and B, respectively (Figure 1). In total, 104

211 eligible patients with IPAH were recruited for this study. Eighteen patients with SLE-PAH

(3.0%) were lost to follow-up and were excluded from the survival analysis.

213 Comparisons of the demographic and clinical characteristics between the SLE-PAH and 214 IPAH groups as well as between SLE-PAH cohorts A and B are shown in Table 1. Compared with patients with IPAH, patients with SLE-PAH were younger $(35.2 \pm 9.9 \text{ vs.})$ 215 216 41.8 ± 16.2 years, p < 0.001) and more predominantly female (98.5% vs. 69.2%, p < 0.001). Pulmonary hypertension in patients with SLE-PAH was less severe than that in 217 218 patients with IPAH, with fewer patients presenting with manifestations such as exertional dyspnoea and syncope, better exercise capacity, lower NT-proBNP level, less right 219 ventricular dilation or reduced right ventricular function on echocardiography, and a better 220 221 overall hemodynamic profile.

The demographic characteristics and SLEDAI were similar between SLE-PAH cohorts A and B. Patients in cohort B showed better performance in terms of 6-MWD ($418 \cdot 1 \pm 132 \cdot 5$ vs. $388 \cdot 9 \pm 134 \cdot 3$ m, p = 0.041), a smaller mean right ventricular diameter ($27 \cdot 1 \pm 7 \cdot 1$ vs. $29 \cdot 9 \pm 7 \cdot 4$ mm, p = 0.011), and less pericardial effusion ($35 \cdot 9\%$ vs. $49 \cdot 6\%$, p = 0.002) on TTE as well as improved hemodynamics with a lower mPAP ($44 \cdot 3 \pm 11 \cdot 4$ vs. $46 \cdot 6 \pm 11 \cdot 8$ mmHg, p = 0.017), lower PVR ($8 \cdot 9 \pm 4 \cdot 9$ vs. $10 \cdot 8 \pm 5 \cdot 3$ WU, p < 0.001), and preserved CI 228 $(3 \cdot 0 \pm 0.9 \text{ vs. } 2 \cdot 8 \pm 0.9 \text{ L/min/m}^2, \text{ p} = 0.001)$. More patients in cohort B presented with a 229 low-risk profile than those in cohort A at baseline; however, the percentage of high-risk 230 patients was similar between the two cohorts (Table 1 and Supplement Figure 1).

231

232 Initial treatment regimen of patients with SLE-PAH

233 As shown in Table 2, most patients with SLE-PAH were treated with glucocorticoids 234 (99.0%) or immunosuppressants (93.6%). Compared to cohort A, more patients in cohort B were treated with intensive immunosuppressive therapy (IIT) (79.7% vs 67.0%, p < 235 0.001), defined as one or more immunosuppressants, including cyclophosphamide (CYC), 236 237 calcineurin inhibitors (CNIs), and mycophenolate mofetil (MMF). More patients in cohort B were treated with PAH-targeted therapy (90.9% vs. 67.2%, p < 0.001) and dual 238 PAH-targeted therapy (41.9% vs. 12.7%, p < 0.001). We then compared the initial 239 treatment regimen between cohort A and cohort B in different risk groups, and showed the 240 significant difference in low to intermediate group (Supplement Table 3). There was no 241 242 significant difference in the high-risk group between cohort A and B.

243

244 Prognosis of patients with SLE-PAH and patients with IPAH

The average follow-up time of patients with SLE-PAH was 4.6 ± 3.0 years. A total of 110 patients with SLE-PAH (18.0%) died during the follow-up. The 5- and 10-year survival rates of SLE-PAH were 81.2% and 66.6%, respectively, which were significantly higher than patient with IPAH (61.7% and 44.1%, respectively, p < 0.001, Figure 2A). Among patients with SLE-PAH, the overall survival rate was significantly higher in cohort B than in cohort A (p = 0.006, Figure 2B). The 1-, 3-, and 5-year survival rates were 93.2%, 85.0%, and 77.5%, respectively, in cohort A and 96.2%, 91.4%, and 88.1%, respectively, in cohort B. When comparing survival between SLE-PAH cohorts A and B stratified into different risk groups, an improvement in survival was observed in the low- and intermediate-risk groups (5-year survival rate 81.7% vs. 89.5%, p = 0.023, Figure 2D) but not in the high-risk group (5-year survival rate 35.4% vs. 69.5%, p = 0.160, Figure 2E).

During follow-up, 304 patients with SLE-PAH (66·1%) reached low-risk PAH profile and 287 (82·0%) patients reached LLDAS. Compared with cohort A, more patients in cohort B reached low-risk profile of PAH (Figure 2C, p < 0·001). The median time of reaching LLDAS was significantly shorter in cohort B compared with cohort A (11·5 ± 1·0 vs. 29·7 ± 2·4, p < 0·001).

261

262 **Prognostic factors for patients with SLE-PAH**

Univariate analysis was used to identify prognostic factors for SLE-PAH. Baseline characteristics, including PAH as an onset symptom of SLE, WHO-FC III–IV, reduced 6-MWD, elevated NT-proBNP concentration, elevated uric acid, elevated total bilirubin, increased PVR, reduced CI, large right ventricular diameter, presence of pericardial effusion, and diffusing capacity of the lung for carbon monoxide of <45% of the predicted value were prognostic factors associated with all-cause mortality (Supplement Table 4).

As shown in Table 3, after adjusting for confounding factors, including age, sex, and CI,

reaching a low-risk profile of PAH was independently associated with a reduced risk of death (hazard ratio [HR] 0.34, 95% confidence interval [CI] 0.15-0.79, p = 0.012). LLDAS, a widely accepted treatment goal for SLE, was also favourably associated with better survival (HR 0.33, 95% CI 0.14-0.82, p = 0.016) in muti-variant time-dependent Cox regression.

To further explore the prognostic value of initial treatment regimens in patients with SLE-PAH, we compared the rate of reaching low-risk profile of PAH between propensity score-matched patients with SLE-PAH who were initially treated with and without IIT, as well as between patients who received mono PAH-targeted therapy versus dual PAH-targeted therapy. Notably, patients who were initially treated with IIT (Figure 3A, p < 0.001) and dual PAH-targeted therapy (Figure 3B, p = 0.038) were more likely to reach low-risk profile of PAH during follow-up.

282

283 **Discussion**

In this multi-center prospective cohort study of patients with SLE-PAH, we compared changes in baseline characteristics, initial treatment regimens, and overall survival over the last decade. We also identified factors associated with prognosis. We found that more patients were diagnosed at an earlier stage of PAH and were treated with IIT and PAH-targeted therapies in the last five years. Survival rates for SLE-PAH have extensively improved over the past decade. Notably, achieving low-risk profile for PAH and LLDAS for SLE were identified as independent predictors of survival in patients with SLE-PAH. 291 Patients treated with IIT and dual PAH-targeted therapy were more likely to achieve a low292 risk profile for PAH during follow-up.

Previous studies have suggested that patients with SLE-PAH have much better short-term 293 outcomes than those with IPAH or SSc-PAH. Chung et al.⁹ compared the clinical 294 characteristics, hemodynamics, and 1-year survival of patients with SLE-PAH (n = 110) 295 with those of patients with SSc-PAH (n = 399) and IPAH (n = 1196) in the Registry to 296 297 Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL registry). They showed that patients with SLE-PAH had better hemodynamics 298 299 and 1-year survival (94% vs. 93%) than those with IPAH. In addition, patients with 300 SLE-PAH had a significantly higher 1-year survival rate than those with SSc-PAH (94% vs. 82%; p = 0.0009). Our results showed that the long-term survival of patients with 301 SLE-PAH was significantly better than patients with IPAH (5-year survival 81.2% vs. 302 303 61.7%, p < 0.001; 10-year survival 66.6% vs. 44.1%, p < 0.001). A Favourable trend in 304 overall survival has also been observed in patients with SLE-PAH over the last decade, consistent with IPAH⁴ and SSc-PAH⁷. 305

Consistent with previous studies that emphasised the importance of goal-oriented treatment of PAH^{12, 21}, we proved that reaching a low-risk profile of PAH, which was recommended as a treatment goal during follow-up by the 2022 ECS/ERS Guidelines¹⁸. was a protective factor for survival in SLE-PAH. Moreover, SLE-PAH is more complicated than other forms of PAH in terms of the underlying autoimmunity and inflammation at its onset and progression. Therefore, achieving the treatment goals for SLE should be emphasised. LLDAS is an attainable treatment target for SLE, based on the principle of an "acceptable"

313 level of disease activity in patients treated with low-dose glucocorticoids and stable 314 immunosuppressive treatments. Achieving LLDAS was proven to be associated with a lower frequency of SLE flares in a previous large cohort study as well as a decreased 315 probability of organ damage, better quality of life, and reduced mortality²². For the first 316 317 time, our study demonstrated that achieving LLDAS was markedly associated with reduced mortality risk in patients with SLE-PAH. A higher proportion of patients in cohort 318 319 B achieved a low-risk profile of PAH and reached the LLDAS of SLE during follow-up, which partially explains the improvement in survival in the last decade. Therefore, a 320 321 goal-oriented dual treat-to-target strategy is recommended for the management of 322 SLE-PAH to achieve better long-term outcomes.

Timely and effective application of PAH-targeted therapy and immunosuppressive therapy 323 324 contribute to the achievement of treatment goals. Upfront dual PAH-targeted therapy was recommended for the initial treatment of PAH based on the improvements in patient 325 326 outcomes observed in the AMBITION (A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension) trial²³. Upfront 327 dual PAH-targeted therapy was favourably associated with a low-risk state of PAH in our 328 study. Besides PAH-targeted medication, our study also showed that more patients were 329 330 able to achieve the PAH treatment goal when treated with IIT as part of the baseline 331 treatment. Previous studies have demonstrated the important role of autoimmune processes in PAH development, especially in the early phase before right heart reconstruction⁶. 332 333 Several retrospective studies have examined the use of immunosuppressive agents in CTD-PAH, suggesting that immunosuppressants are associated with improvements in 334

survival⁶. 335 exercise capacity, hemodynamics, and long-term Responders to immunosuppressive therapy were mostly in the early stage of PAH²⁴. Our results indicate 336 that early initiation of IIT may reverse PAH progression and help achieve a low-risk state. 337 338 Thus, IIT should be considered to have the same importance as PAH-targeted therapy in the management of patients with SLE-PAH. Apart from traditional immunosuppressive 339 drugs, biological agents, including rituximab, belimumab, telitacicept, tocilizumab, and 340 341 JAK inhibitors, for which indications are increasing in patients with SLE with different organ involvement, may also have potential therapeutic benefits for SLE-PAH⁶. A 342 randomised clinical trial of rituximab demonstrated that patients with SSc-PAH and 343 elevated cytokine levels showed improvement in both the 6-MWD and PVR at 24 weeks²⁵, 344 ²⁶. Therefore, we believe that it is especially worthwhile to explore the treatment effects in 345 346 patients with SLE-PAH, considering that this condition has more prominent inflammation than SSc-PAH. 347

Early detection is also essential to achieve treatment goals. In the present study, patients in 348 349 cohort B had better clinical and hemodynamic states, indicating that more patients were diagnosed and treated at an early stage of PAH. Interestingly, a recent multi-center cohort 350 study conducted in China that recruited patients from cardiovascular centers showed that 351 352 the overall survival of patients with CTD-PAH was comparable to that of patients with IPAH. Although SSc-PAH accounted for a very small proportion (7.1%) of this cohort, the 353 5-year survival rate was still much worse than that of patients in the present study 354 (approximately 70% vs. 81.2%)³. This may be partly related to the fact that patients 355 referred to cardiovascular centers primarily had symptomatic PAH. Since PAH develops 356

357 occultly in patients with SLE in most cases, clinical factors and serological biomarkers are 358 studied to identify SLE patients at risk and allow early detection of PAH. Previous studies have suggested that Raynaud's phenomenon, serositis, hyperuricaemia, anti-RNP, 359 anti-SSA/SSB, and antiphospholipid antibodies are risk factors for SLE-PAH²⁷⁻²⁹. Recently. 360 a risk-stratification model incorporating routine clinical parameters to predict the risk of 361 PAH in patients with SLE was developed²⁹. Genetic studies have shown that 362 HLA-DQA1*03:02 is a genetic risk of SLE-PAH³⁰. Patients with the above risk factors or 363 those deemed to be high risk by the algorithm were recommended annual TTE screening to 364 detect signs of pulmonary hypertension. 365

This study has some limitations. Firstly, the long-term survival of patients with high-risk 366 group has a tendency of improvement, however, without statistical significance, which 367 could be partly explain by the limited number of patients in this group. Future study is 368 needed focusing the high-risk group of patients and studying the prognostic value of dual 369 370 treat-to-target strategy. Secondly, for the nature of a real-world study, the prognostic value 371 of treatment was evaluated by using risk-matching analysis. To further study the treatment strategy of SLE-PAH, randomized clinical trials are needed. Finally, as disease 372 characteristics and prognosis of SLE-PAH may vary among different populations, we 373 374 called for global cohort study of SLE-PAH to expand the research populations and further 375 explore the possible racial difference of this disease.

Taken together, this is the largest prognostic study of SLE-PAH, based on the CSTAR-PAH
cohort. Our findings, for the first time, illustrated the progress made in the early detection
and management of patients with SLE-PAH over the last decade, which led to significant

improvements in survival. We emphasised that meeting the treatment goals of both SLE
and PAH were independently associated with reduced mortality, which support the dual
treat-to-target strategy in SLE-PAH. Iinitial use of IIT, together with PAH-targeted
combination therapy contributed to the early achievement of PAH treatment goals, which
are recommended to implement in the real clinical practice of SLE-PAH.

384

385 Acknowledgements

The authors thank all investigators, study coordinators, and patients who participated in the 386 387 study. Jiuliang Zhao, Qian Wang, Mengtao Li, and Xiaofeng Zeng conceived and designed the study. Xingbei Dong, Junyan Qian, Wei Wei, Miaojia Zhang, Xiao Zhang, Xiaofei Shi, 388 Yisha Li, Xiaoping Hong, Qiang Shu, Shuhong Chi, Xin Dong, Ping Zhu, Rong Zhang, 389 390 Zhuoli Zhang, Hongfeng Zhang, Xinwang Duan, Jing Xue, Shuhong Zhou, Hongbin Li, Dan Chen, Junwei Zhang, Zhuang Tian, Yongtai Liu collected patient data. Xingbei Dong, 391 Junyan Qian, Jiuliang Zhao and Yanhong Wang analyzed data. All authors interpreted the 392 results. Xingbei Dong, Jiuliang Zhao, Junyan Qian, Qian Wang, and Mengtao Li wrote the 393 394 manuscript. All authors critically reviewed and revised the manuscript and approved the final version for publication. All authors had full access to the study data and final 395 responsibility for the decision to submit for publication. 396

397 Source of fundings

This study was supported by the Chinese National Key Technology R&D Program,
Ministry of Science and Technology (2021YFC2501300, 2017YFC0907600), Beijing

Municipal Science & Technology Commission (No. Z201100005520022, 23, 25-27), 400 401 CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-005, 2019-12M-2-008), and National High Level Hospital Clinical Research Funding 402 403 (2022-PUMCH-B-013, C-002, D-009, A-228). The sponsors of the study were not involved in the study design, data collection, data analysis, interpretation of data, writing 404 405 of the report, or decision to submit the paper for publication.

406 Disclosures

407 The authors declare no conflict of interest.

408 **References**

- 1. Hassoun PM. Pulmonary Arterial Hypertension. *N Engl J Med.* 2021;385:2361-2376.
- 410 2. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ,
- 411 Benza RL, Liou TG, Turner M, et al. Pulmonary arterial hypertension: baseline
 412 characteristics from the REVEAL Registry. *Chest.* 2010;137:376-87.
- 3. Quan R, Zhang G, Yu Z, Zhang C, Yang Z, Tian H, Yang Y, Wu W, Chen Y, Liu Y, et al.
 Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in
 China: Insights from a national multicentre prospective registry. *Respirology*.
 2022;27:517-528.
- 417 4. Hoeper MM, Pausch C, Grunig E, Staehler G, Huscher D, Pittrow D, Olsson KM,
 418 Vizza CD, Gall H, Distler O, et al. Temporal trends in pulmonary arterial hypertension:
- 419 results from the COMPERA registry. *Eur Respir J.* 2022;59.
- 420 5. Aithala R, Alex AG and Danda D. Pulmonary hypertension in connective tissue
 421 diseases: an update. *Int J Rheum Dis*. 2017;20:5-24.
- 422 6. Zhao J, Wang Q, Deng X, Qian J, Tian Z, Liu Y, Li M and Zeng X. The treatment
 423 strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving
 424 into the future. *Pharmacol Ther*. 2022;239:108192.
- 425 7. Hassan HJ, Naranjo M, Ayoub N, Housten T, Hsu S, Balasubramanian A, Simpson CE,
- 426 Damico RL, Mathai SC, Kolb TM, et al. Improved Survival for Patients with Systemic
- 427 Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry. Am J
- 428 *Respir Crit Care Med.* 2022.
- 429 8. Hao YJ, Jiang X, Zhou W, Wang Y, Gao L, Wang Y, Li GT, Hong T, Huo Y, Jing ZC, et

- 430 al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese
 431 patients. *Eur Respir J.* 2014;44:963-72.
- 432 9. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls
- 433 MR and Zamanian RT. Characterization of connective tissue disease-associated pulmonary
- 434 arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
 435 *Chest.* 2010;138:1383-94.
- 436 10. Hachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D, Cottin V, Habib G,
- 437 Prevot G, Chabanne C, et al. Pulmonary Arterial Hypertension Associated With Systemic
- 438 Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. *Chest.*439 2018;153:143-151.
- 11. Zhao J, Wang Q, Liu Y, Tian Z, Guo X, Wang H, Lai J, Huang C, Yang X, Li M, et al.
 Clinical characteristics and survival of pulmonary arterial hypertension associated with
 three major connective tissue diseases: A cohort study in China. *Int J Cardiol.*2017;236:432-437.
- 444 12. Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, Wei W, Zuo X, Zhang M, Zhu P, et al.
 445 Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary
 446 arterial hypertension: CSTAR-PAH cohort study. *European Respiratory Journal*. 2019;53.
- Wang Q, Qian J, Li M, Zhang X, Wei W, Zuo X, Zhu P, Ye S, Zhang W, Zheng Y, et al.
 Risk assessment in systemic lupus erythematosus-associated pulmonary arterial
 hypertension: CSTAR-PAH cohort study. *Ther Adv Chronic Dis.*2022;13:20406223221112528.
- 14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal

- 452 N and Winchester RJ. The 1982 revised criteria for the classification of systemic lupus
 453 erythematosus. *Arthritis Rheum*. 1982;25:1271-7.
- 454 15. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg
- D, Wallace DJ, Nived O, et al. Derivation and validation of the Systemic Lupus
 International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum.* 2012;64:2677-86.
- 458 16. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ,
- 459 Sander CR, Ratoff J, Devaraj A, et al. Interstitial lung disease in systemic sclerosis: a
 460 simple staging system. *Am J Respir Crit Care Med*. 2008;177:1248-54.
- 461 17. Ibañez D, Gladman DD and Urowitz MB. Adjusted mean Systemic Lupus
 462 Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. *J Rheumatol*.
 463 2005;32:824-7.
- 18. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J,
- 465 Coats AJS, Escribano-Subias P, Ferrari P, et al. 2022 ESC/ERS Guidelines for the 466 diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022;43:3618-3731.
- 467 19. Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grunig E, Staehler G,
- 468 Vizza CD, Gall H, Distler O, et al. COMPERA 2.0: a refined four-stratum risk assessment
- 469 model for pulmonary arterial hypertension. *Eur Respir J.* 2022;60.
- 470 20. Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS,
- 471 Chen SL, Jin O, Morton S, et al. Definition and initial validation of a Lupus Low Disease
- 472 Activity State (LLDAS). Ann Rheum Dis. 2016;75:1615-21.
- 473 21. Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S,

- Wikstrom G and Radegran G. A comprehensive risk stratification at early follow-up
 determines prognosis in pulmonary arterial hypertension. *Eur Heart J.* 2018;39:4175-4181.
- 476 22. Samoes B, Zen M, Abelha-Aleixo J, Gatto M and Doria A. Caveats and pitfalls in
 477 defining low disease activity in systemic lupus erythematosus. *Autoimmun Rev.*478 2022;21:103165.
- 479 23. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock
 480 AJ, Simonneau G, Vachiery JL, Grunig E, et al. Initial Use of Ambrisentan plus Tadalafil in
 481 Pulmonary Arterial Hypertension. *N Engl J Med.* 2015;373:834-44.
- 482 24. Ding Y, Qian J, Zhang S, Xu D, Leng X, Zhao J, Wang Q, Zhang W, Tian X, Li M, et
 483 al. Immunosuppressive therapy in patients with connective tissue disease-associated
 484 pulmonary arterial hypertension: A systematic review. *Int J Rheum Dis.* 2022.
- 485 25. Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A,
- 486 Keyes-Elstein L, D'Aveta C, Spychala M, White RJ, et al. Safety and Efficacy of B-Cell
- 487 Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary
- 488 Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.
- 489 *Am J Respir Crit Care Med.* 2021;204:209-221.
- 26. Zhang Y and Michelakis ED. A Phase-2 NIH-sponsored Randomized Clinical Trial of
 Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach
 Significance for Its Endpoints: End of Story? Not So Fast! *Am J Respir Crit Care Med.*2021;204:123-125.
- 494 27. Kim JS, Kim D, Joo YB, Won S, Lee J, Shin J and Bae SC. Factors associated with 495 development and mortality of pulmonary hypertension in systemic lupus erythematosus

- 496 patients. *Lupus*. 2018;27:1769-1777.
- 497 28. Zhang N, Li M, Qian J, Wang Q, Zhao J, Yang Z, Tian Z, Zhang X, Zuo X, Zhang M,
- 498 et al. Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-
- 499 PAH study: Baseline characteristics and risk factors. International Journal of Rheumatic
- 500 *Diseases*. 2019;22:921-928.
- 501 29. Qu J, Li M, Wang Y, Duan X, Luo H, Zhao C, Zhan F, Wu Z, Li H, Yang M, et al.
- 502 Predicting Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus:
- 503 CSTAR Cohort Study. *Arthritis Rheumatol*. 2021.
- 30. Qian J, Chen Y, Yang X, Wang Q, Zhao J, Deng X, Ding Y, Li S, Liu Y, Tian Z, et al.
- 505 Association study identified HLA-DQA1 as a novel genetic risk of systemic lupus 506 erythematosus-associated pulmonary arterial hypertension. *Arthritis Rheumatol*. 2023.




Figure 1. Study flow diagram. SLE, systematic lupus erythematosus; PH, pulmonary
hypertension; CSTAR, Chinese SLE Treatment and Research Group; mPAP, mean
pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary
vascular resistance; WU, wood units; RHC, right heart catheterization; WSPH, World
Symposium on Pulmonary Hypertension; PAH, pulmonary arterial hypertension.




Figure 2. Kaplan–Meier survival analysis. (A) Comparison of 10-year survival between
patients with SLE-PAH and patients with IPAH. (B) Comparison of 5-year survival
between cohorts A and B. Comparison of 5-year survival between patients with SLE-PAH
in (C) Comparison of rate of achieving low-risk profile of PAH during follow-up between

519	cohorts A and B. (D) Comparison of 5-year survival between cohort A and B in low and
520	intermediate-risk groups and (E) in high-risk group. SLE, systemic lupus erythematosus;
521	PAH, pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension




Figure 3. Comparison of rate of achieving low-risk profile of PAH during follow-up
between propensity score-matched groups. (A) Comparison with and without IIT and (B)
with mono- versus dual PAH-targeted therapy. PAH, pulmonary arterial hypertension; IIT,
intensive immunosuppressive therapy.

	SLE-PAH vs. IPAH			Cohort A vs. Cohort B
	SLE-PAH	IPAH	p-value	cohort A cohort B p-value
	(n=610)	(n=104)	p value	(n=314) (n=296)
Age at enrolment (years)	$35 \cdot 2 \pm 9 \cdot 9$	41·8±16·2	<0.001	34·8±9·9 35·5±10·0 0·431
Female	601 (98.5%)	72 (69·2%)	<0.001	312 (99.4%) 289 (97.6%) 0.098
Duration since onset of SLE (years)	4·4±5·5	NA	NA	4.3 ± 5.5 4.5 ± 5.5 0.790
Symptoms				
Exertional dyspnoea	497 (81.5%)	82 (97.6%)	<0.001	263 (83.8%) 234 (79.1%) 0.145
Syncope	57 (9.3%)	19 (18.4%)	0.007	25 (8.0%) 32 (10.8%) 0.266
Functional state				
WHO FC III-IV	254 (47.1%)	37 (35.9%)	0.040	133 (48.7%) 121 (45.5%) 0.490
6-MWD (m)	400·5±134·2	350·5±131·2	0.002	388·9±134·3 418·1±132·5 0·041
Laboratory findings				

Table 1. Baseline characteristics of patients with SLE-PAH and patients with IPAH

NT = 0		1923·2±3059·7	2715·3±2839·2	0.027	1862·8±2640·6	1974·3±3378	0.711
	NT-proBNP (ng/L)					·8	
	Uric acid (µmol/L)	376·4±143·6	442·7±151·7	<0.001	366·5±127·7	388·7±160·5	0.108
	Total Bilirubin (µmol/L)	13·4±16·1	19·8±12·5	<0.001	12·7±8·9	14·2±21·3	0.290
Не	modynamic						
	mPAP (mmHg)	45·5±11·7	56·3±16·9	<0.001	46·6±11·8	44·3±11·4	0.017
	PAWP (mmHg)	8·4±3·5	9·2±3·4	0.037	7·8±3·6	9·0±3·4	<0.001
	PVR (WU)	$9 \cdot 8 \pm 5 \cdot 2$	15·0±9·3	<0.001	10·8±5·3	8·9±4·9	<0.001
	RAP (mmHg)	$6 \cdot 5 \pm 4 \cdot 1$	8·3±6·4	0.055	6·3±4·2	6·7±3·9	0.306
	CI (L/min·m ²)	$2 \cdot 9 \pm 0 \cdot 9$	2·2±0·8	<0.001	2·8±0·9	3·0±0·9	0.001
Ec	hocardiography						
	RV diameter (mm)	29·1±7·4	33·3±6·6	0.078	29·9±7·4	27.7±7.1	0.011
	TRV (m/s)	$4 \cdot 1 \pm 0 \cdot 7$	4·4±0·6	<0.001	4·1±0·6	4·0±0·7	0.013
	Estimated PASP (mmHg)	75·6±21·0	90·2±21·7	<0.001	77·8±20·6	73·0±21·2	0.008

Pericardial effusion	229 (43.1%)	29 (36.3%)	0.275	139 (49.6%) 90 (3	35·9%) 0·002
Pulmonary function test					
FVC, (% predicted)	83·3±14·6	95·1±16·0	<0.001	80·7±13·3 90·9	9±15·4 < 0·001
TLC, (% predicted)	89·1±11·9	96·2±12·3	<0.001	88·5±11·0 90·6	5±14·2 0·292
DLCO, (% predicted)	60·4±15·4	63·2±24·3	0.297	61·0±15·7 59·1	±14·6 0·453
SLEDAI (points)	5.9±5.8	NA	NA	6·0±5·5 5·8	8±6·2 0·557
Risk stratification					
Low risk	262 (43.4%)	14 (13.6%)	<0.001	120 (38.8%) 142 (48·3%) 0·021
Intermediated risk	293 (48.6%)	72 (69.9%)	<0.001	163 (52.8%) 130 (44·2%) 0·042
High risk	48 (8.0%)	17 (16.5%)	0.008	26 (8.4%) 22 (7.5%) 0.764

528 * SLE, systemic lupus erythematosus; PAH, pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; BMI, body mass 529 index; WHO, World Health Organization; FC, function class; 6-MWD, 6-minute walk distance; NT-proBNP, N-terminal prohormone brain 530 natriuretic peptide; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RAP, 531 right atrial pressure; CI, cardiac index; RV, right ventricle; TRV, tricuspid regurgitant velocity; PASP, pulmonary arterial systolic pressure; FVC, 532 forced vital capacity; TLC, total lung capacity; DLCO, diffusing capacity for carbon monoxide; SLEDAI, SLE Disease Activity Index; NA, not 533 available.

Table 2. Initial treatment regimen for patients with SLE-PAH

	SLE-PAH	cohort A	cohort B	
	(n=610)	(n=314)	(n=296)	p-value
Glucocorticoid	595 (99.0%)	308 (99.7%)	287 (98.3%)	0.113
* High dose	192 (31.9%)	103 (33·3%)	89 (30.5%)	0.484
Low to medium dose	403 (67.1%)	205 (66.3%)	198 (67.8%)	0.729
Immunosuppressants	569 (93.6%)	286 (91.7%)	283 (95.6%)	0.067
† Intensive immunosuppressive therapy	445 (73.2%)	209 (67.0%)	236 (79.7%)	<0.001
PAH-targeted medication	480 (78.7%)	211 (67.2%)	269 (90.9%)	<0.001
Dual combination therapy	164 (26.9%)	40 (12.7%)	124 (41.9%)	<0.001
Triple combination therapy	12 (2.0%)	3 (1.0%)	9 (3.0%)	0.081
ERA	309 (50.7%)	115 (36.6%)	194 (65.5%)	<0.001
PDE5i/ sGC	327 (53.6%)	127 (40.4%)	200 (67.6%)	<0.001

534 * High dose glucocorticoid was defined as prednisone (or equivalent) dose $\geq 1 \text{ mg/kg/d}$.

535 †Intensive immunosuppressive therapy was defined as one or more immunosuppressants, including cyclophosphamide, calcineurin

536 inhibitors, and mycophenolate mofetil.

PCA

- 537 **‡** SLE, systemic lupus erythematosus; PAH, pulmonary arterial hypertension; ERA, endothelin receptor antagonist; PDE5i,
- 538 phosphodiesterase-5 inhibitor; sGCS, soluble guanylate cyclase stimulator; PCA, prostacyclin analogue.

	Univariable ar	nalysis	Multivariable analysis		
	HR (95%CI)	p-value	HR (95%CI)	p-value	
*Reaching low-risk profile of PAH	0.22 (0.13-0.37)	<0.001	0.34 (0.15-0.79)	0.012	
*Reaching LLDAS of SLE	0.22 (0.10-0.47)	<0.001	0.33 (0.14-0.82)	0.016	
Age at enrolment (per year)	1.02 (1.00-1.04)	0.060	1.04 (0.99-1.08)	0.084	
Female	0.54 (0.13-2.18)	0.383	0.11 (0.01-0.91)	0.040	
$CI < 2.0 L/min \cdot m^2$	3.74 (2.44-5.73)	<0.001	2.08 (0.96-4.54)	0.064	

539 Table 3. Predictors of all-cause mortality in patients with SLE-PAH

540 * Time-dependent covariates

541 + SLE, systemic lupus erythematosus; PAH, pulmonary arterial hypertension; LLDAS, low lupus disease activity state;

542 CI, cardiac index